138 related articles for article (PubMed ID: 25168203)
1. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.
Sobbe A; Bridle KR; Jaskowski L; de Guzman CE; Santrampurwala N; Clouston AD; Campbell CM; Subramaniam VN; Crawford DH
J Gastroenterol Hepatol; 2015 Mar; 30(3):638-45. PubMed ID: 25168203
[TBL] [Abstract][Full Text] [Related]
2. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
[TBL] [Abstract][Full Text] [Related]
3. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
4. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox--an oral agent for chronic iron overload.
Vanorden HE; Hagemann TM
Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
[TBL] [Abstract][Full Text] [Related]
6. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.
Otto-Duessel M; Aguilar M; Nick H; Moats R; Wood JC
Exp Hematol; 2007 Jul; 35(7):1069-73. PubMed ID: 17588475
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
Al-Rousan RM; Rice KM; Katta A; Laurino J; Walker EM; Wu M; Triest WE; Blough ER
Transl Res; 2011 Jun; 157(6):368-77. PubMed ID: 21575921
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
[TBL] [Abstract][Full Text] [Related]
10. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse.
Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Yanase K; Namisaki T; Imazu H; Fukui H
Hepatology; 2002 Oct; 36(4 Pt 1):850-60. PubMed ID: 12297832
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
[TBL] [Abstract][Full Text] [Related]
13. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.
Guariglia R; Martorelli MC; Villani O; Pietrantuono G; Mansueto G; D'Auria F; Grieco V; Bianchino G; Lerose R; Bochicchio GB; Musto P
Leuk Res; 2011 May; 35(5):566-70. PubMed ID: 21185078
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
[TBL] [Abstract][Full Text] [Related]
15. Antifibrotic effects of a recombinant adeno-associated virus carrying small interfering RNA targeting TIMP-1 in rat liver fibrosis.
Cong M; Liu T; Wang P; Fan X; Yang A; Bai Y; Peng Z; Wu P; Tong X; Chen J; Li H; Cong R; Tang S; Wang B; Jia J; You H
Am J Pathol; 2013 May; 182(5):1607-16. PubMed ID: 23474083
[TBL] [Abstract][Full Text] [Related]
16. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
17. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice.
Yoshida S; Ikenaga N; Liu SB; Peng ZW; Chung J; Sverdlov DY; Miyamoto M; Kim YO; Ogawa S; Arch RH; Schuppan D; Popov Y
Gastroenterology; 2014 Dec; 147(6):1378-92. PubMed ID: 25173753
[TBL] [Abstract][Full Text] [Related]
18. Exjade (ICL 670): A new oral iron chelator.
Agarwal MB
J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
[TBL] [Abstract][Full Text] [Related]
19. Iron chelation therapy as a treatment for Pythium insidiosum in an animal model.
Zanette RA; Alves SH; Pilotto MB; Weiblen C; Fighera RA; Wolkmer P; Flores MM; Santurio JM
J Antimicrob Chemother; 2013 May; 68(5):1144-7. PubMed ID: 23329785
[TBL] [Abstract][Full Text] [Related]
20. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
